VEGFA and pneumothorax: Pazopanib, approved primarily for metastatic soft tissue sarcoma, inhibits vascular endothelial growth factor (VEGF) pathways, impacting tumor growth and vascularization, but can lead to unique adverse effects such as pneumothorax, a complication scarcely reported in other TKIs of the same class [5].